March 2025 in “International Journal of Trichology” Injecting stem cells from a patient's own fat can improve hair growth in women with hair loss.
1 citations
,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
April 2023 in “World Journal of Advanced Research and Reviews” Frequent blood transfusions in beta thalassemia can lead to thyroid problems.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
165 citations
,
September 2013 in “Contemporary Clinical Trials”
April 2018 in “Journal of Cosmetic and Laser Therapy” The editorial introduces studies on various cosmetic and laser treatments, their effectiveness, and posttreatment care.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
September 2022 in “Journal of Ayub Medical College Abbottabad” Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.
2 citations
,
April 2024 in “International Wound Journal” Combining UV therapy with PRP heals chronic wounds faster and reduces pain.
19 citations
,
January 2006 in “Indian Journal of Dermatology” The document's conclusion cannot be provided because the content is not accessible.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
7 citations
,
August 2022 in “Nature communications” A specific group of slow-growing stem cells marked by Thy1 is crucial for skin maintenance and healing in mice.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
3 citations
,
October 2024 in “Cancers” Skin side effects from melanoma immunotherapy are common and may indicate better survival.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
1 citations
,
January 2021 Non-invasive methods can effectively monitor skin inflammation and cancer biomarkers.
7 citations
,
January 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” T-cell reconstitution after thymus transplantation can cause hair whitening and loss.
May 2026 in “International Journal of Molecular Sciences” The new human placental extract may help prevent hair graying and reduce nerve pain from chemotherapy.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
April 2010 in “The journal of immunology/The Journal of immunology” FoxN1 gene is crucial for proper thymus structure and normal skin appearance.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
August 2010 in “The Journal of Dermatology” The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.
6 citations
,
May 2000 in “Pediatric Dermatology” KID syndrome should be reclassified as an ectodermal dysplasia.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.